

Procter & Gamble - Intellectual Property Division**RECEIVED**
CENTRAL FAX CENTER**AUG 09 2004****IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

**FACSIMILE TRANSMITTAL SHEET &
CERTIFICATE OF TRANSMISSION UNDER 37 CFR §1.8****OFFICIAL**

TO: Commissioner for Patents
Attn: Examiner William W. Moore
Fax No. (703) 872-9306
Phone No. (571) 272-0933

*I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on **August 9, 2004**, to the above-identified facsimile number.*

 (Signature)

FROM: Laura L. Frieko
Fax No. (513) 626-1355
Phone No. (513) 626-2721

Listed below are the item(s) being submitted with this Certificate of Transmission:

- 1) Transmittal for Response;
- 2) Response (3 pages)

Number of Pages Including this Page: 5

Inventor(s): Rubingh et al.
S.N.: 09/618,235
Filed: 7/18/2000
Conf. No.: 8554
Case: 7670

Comments:

To Whom It May Concern:

IN THE UNITED STATES PATENT & TRADEMARK OFFICE
RESPONSE/AMENDMENT

Case Docket No. 7670

Mail Stop AF
COMMISSIONER FOR PATENTS
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is a RESPONSE/AMENDMENT for the patent application:

Inventor(s): D. N. Rubingh et al. Confirmation No. 8644
Serial No.: 09/618,235 Group Art Unit: 1652
Date Filed: 7/18/2000 Examiner: W. W. Moore
Title: Protease Conjugates Having Sterically Protected Epitope Regions

1. ☒ No additional fee is known to be required.
2. ☐ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)	OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA*	RATE	FEE
TOTAL	* 21	MINUS	** 21	=	x \$18 =	\$
INDEP.	* 01	MINUS	*** 01	=	x \$80 =	\$
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ \$270 =	\$
					TOTAL	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the highest number of total claims previously paid for is less than 20, write "20" in this space.

*** If the highest number of independent claims previously paid for is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

3. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is attached.
 - a. ☒ Any patent application processing fees under 37 CFR §1.16.
 - b. ☒ Any patent application processing fees under 37 CFR §1.17.
4. The Commissioner is hereby authorized to make any additional copies of this sheet needed to accomplish the purposes provided for herein and to charge any fee for such copies to Deposit Account No. 16-2480.



Laura L. Frieko
Registered Patent Agent
Registration No. 52,920
Tel. No. (513) 626-2721

August 9, 2004

Customer No. 27752

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

AUG 09 2004

Application No. : 09/618,235
Applicant(s) : D. N. Rubingh et al.
Filed : July 18, 2000
Title : PROTEASE CONJUGATES HAVING STERICALLY
PROTECTED EPITOPE REGIONS
TC/A.U. : 1652
Examiner : W.W. Moore
Conf. No. : 8554
Docket No. : 7670
Customer No. : 27752

OFFICIAL

RESPONSE AFTER FINAL OFFICE ACTION UNDER 37 CFR 81.113

Mail Stop AF
Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Examiner:

In response to the Office Action of June 9, 2004, please consider the following remarks
and reconsider the application.

Remarks begin on page 2 of this paper.